<DOC>
	<DOCNO>NCT02067117</DOCNO>
	<brief_summary>This study aim confirm lot-to-lot consistency 3 consecutive batch 'GC FLU® Pre-filled Syringe Injection ' 'GC FLU® Injection ' lot-to-lot</brief_summary>
	<brief_title>Demonstrate Lot-to-lot Consistency 3 Consecutive Batches Evaluate Efficacy Safety GC FLU®Pre-filled Syringe Injection 'GC FLU®Injection ' Administration .</brief_title>
	<detailed_description>This Post-Marketing , Multicentre , Open , Randomized Phase 4 Clinical Study . Subjects give voluntary write informed consent participate study screen eligibility study , meet eligibility criterion randomize investigational group . An investigator assess effectiveness ( immunogenicity ) safety study vaccine subject his/her participation study . Subjects randomize ( Visit 1 ) investigational group accord randomization table previously generate , vaccinate influenza split vaccine , 'GC FLU®Pre-filled Syringe Injection ' 'GC FLU®Injection ' . 12 Assessments HI titre strain influenza perform Visit 1 ( pre-vaccination ) , Visit 3 ( 21 day vaccination ) efficacy ( immunogenicity ) evaluation [ Picture 1 ] .For safety assessment , subject diary hand subject , instruct record adverse event emerge ager receipt study vaccine .</detailed_description>
	<criteria>Healthy adults≥ 18 &lt; 65years age follow 21 day . Depending part study subject go participate , age criterion divide follow : Lottolot consistency study [ PART A ] : ≥ 18 &lt; 65 year age Annual clinical trial [ PART B ] : ≥ 18 &lt; 65 year age [ adult ] 65 year age [ elderly population ] Subjects give voluntary write consent participate study , able comply study requirement . Subjects know hypersensitivity allergic reaction egg egg product , chicken chichenproducts , component study vaccine , neomycin gentanicin . Subjects immune system disorder , include immune deficiency disease . Subjects history GuillainBarre syndrome . Subjects severe chronic disease ( e.g. , cardiovascular disease except controlled hypertension , respiratory disease , metabolic disease , renal dysfunction hemoglobinopathy , etc . ) investigator 's opinion may difficulty participate study . Subjects haemophilia receive treatment anticoagulant , increased risk serious bleed intramuscular injection . Subjects acute fever body temperature exceed 38.0 °C within 72 hour vaccination study drug . Subjects received vaccination within 7 day vaccination study drug , another vaccination schedule study . Subjects receive immunosuppressant immune modify drug within 3 month vaccination study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>influenza</keyword>
</DOC>